Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Ascendis Pharma Is Rocketing Higher Today

By Cory Renauer - Updated Apr 10, 2019 at 6:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A proprietary extended-release drug-delivery technology may be worth a lot more than anyone expected.

What happened

Shares of Ascendis Pharma (ASND -2.48%), a biopharmaceutical company committed to extended-release technology, are soaring after the company released pivotal trial results for its lead candidate. Investors expecting blockbuster sales have pushed the stock 58.8% higher as of 12:04 p.m. EST on Monday. 

So what 

Annual sales of Pfizer's (PFE -1.63%) Genotropin brand of human growth hormone (HGH) replacement therapy peaked near $900 million around a decade ago, and Ascendis Pharma is probably right to suggest a longer-lasting version could perform much better. Ascendis Pharma stock is on the move today because pivotal trial results comparing a weekly injection of the company's lead candidate, TransCon HGH, suggest it's as good or better than daily injections of Pfizer's HGH. 

Check out the latest earnings call transcript for Ascendis Pharma.

Guy in a suit doing a happy dance as money rains down from the sky.

Image source: Getty Images.

Ascendis set out to prove its weekly injection was just as good, but today's results were a big surprise. After 52 weeks, children injected weekly with TransCon HGH were 0.86 cm taller than those given a daily HGH dose, a statistically significant difference.

Now what

Getting young children ready for each day is tough without adding a needle to their daily routine, and adults aren't too fond of stabbing themselves each day if they can help it. With this in mind, Ascendis thinks the global market opportunity for TransCon HGH can drive blockbuster sales if expanded to include the same patients as gonadotropin.

Growth hormone deficiency isn't the only condition treated with frequent injections of replacement hormones. Ascendis also has two more TransCon extended treatments in clinical-stage testing and enough cash to last a couple more years.

That should be a long enough runway to get its treatment to a commercial stage. The company expects results from a second pivotal study in the second quarter. If successful, as expected, Ascendis will use both to support an application the FDA could see in the first half of 2019. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ascendis Pharma A/S Stock Quote
Ascendis Pharma A/S
ASND
$86.76 (-2.48%) $-2.21
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.51 (-1.63%) $0.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.